Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoparathyroidism

Interventions

DRUG: 400 µg of MBX 2109 once-weekly by subcutaneous injection
DRUG: 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection

Sponsor

MBX Biosciences